Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EBT (2019 - 2025)

C4 Therapeutics' EBT history spans 7 years, with the latest figure at -$20.4 million for Q4 2025.

  • For Q4 2025, EBT rose 40.87% year-over-year to -$20.4 million; the TTM value through Dec 2025 reached -$104.9 million, changed 0.3%, while the annual FY2025 figure was -$104.9 million, 0.3% changed from the prior year.
  • EBT reached -$20.4 million in Q4 2025 per CCCC's latest filing, up from -$32.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$15.7 million in Q4 2021 to a low of -$37.2 million in Q4 2022.
  • Average EBT over 5 years is -$27.6 million, with a median of -$26.6 million recorded in 2022.
  • Peak YoY movement for EBT: plummeted 137.48% in 2022, then skyrocketed 50.68% in 2024.
  • A 5-year view of EBT shows it stood at -$15.7 million in 2021, then tumbled by 137.48% to -$37.2 million in 2022, then grew by 7.28% to -$34.5 million in 2023, then rose by 0.1% to -$34.4 million in 2024, then soared by 40.87% to -$20.4 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's EBT are -$20.4 million (Q4 2025), -$32.2 million (Q3 2025), and -$26.0 million (Q2 2025).